What is Hualan Biological Vaccine Inc.'s (301207.SZ) StockRank?

MoatMap's StockRank for Hualan Biological Vaccine Inc. (301207.SZ) is 48/100, with a Hold signal. This is a composite score combining Quality (56), Value (39), and Momentum (44) factor ranks across MoatMap's 20,000+ stock universe.

Does Hualan Biological Vaccine Inc. have an economic moat?

Hualan Biological Vaccine Inc. (301207.SZ) has a Quality factor score of 56/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Hualan Biological Vaccine Inc. a buy, hold, or sell?

MoatMap's current signal for Hualan Biological Vaccine Inc. (301207.SZ) is Hold, based on a StockRank of 48/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Hualan Biological Vaccine Inc. in?

Hualan Biological Vaccine Inc. (301207.SZ) operates in the Healthcare sector, specifically the Biotechnology industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

301207.SZ

HOLDREMOVE

Hualan Biological Vaccine Inc. · Healthcare · China · $1.6B · Avg Vol: $21M/d

StockRank

P/E (TTM)

53.5x

ROE

3.2%

D/E

—

Dividend %

8.3%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Hualan Biological Vaccine is a domestic Chinese vaccine developer. It lacks the global scale, regulatory validation, and multi-product pricing power of high-conviction CDMOs, making it highly vulnerable to localized price bidding wars.

COMPANY DESCRIPTION

Hualan Biological Vaccine Inc. develops, manufactures, and commercializes human vaccines, with a dominant market position in China's influenza vaccine sector. The company's product portfolio includes quadrivalent influenza vaccines, rabies vaccines, and meningococcal vaccines. Its competitive moat is sustained by high regulatory barriers to entry, advanced biological manufacturing facilities, and a robust R&D pipeline.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	270M	356M	167M	178M	-13.0%
EPS	0.13	0.21	0.05	0.05	-29.6%
Shares	600M	600M	601M	601M	+0.2%
Debt	44M	44M	44M	168M	56.0%
Equity	812M	926M	889M	843M	1.2%
Op CF	43M	131M	69M	53M	7.4%
Inv CF	-259M	-107M	-9M	27M	—
Fin CF	289M	-19M	-63M	-119M	—

PRICE (1M)-22.6%

SMA 50SMA 200

$2.43

RSI (14)

40.6

52W High

$3.93

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

3.3%51.7

ROE

3.2%51.4

GP/Assets

12.8%31.5

Op. Margin

73.1%99.4

FCF/Assets

3.8%65.1

Piotroski

—83.4

Int. Cover

50.0x91.5

D/E Ratio

—N/A

Current Ratio

4.14x65.0

Value

P/E (TTM)

53.5x18.7

EV/EBITDA

32.0x11.0

P/FCF

284.4x29.4

P/B

1.7x60.8

P/S

8.3x29.6

Div Yield

8.3%97.8

Momentum

52W High %

62%43.0

RS 6M

-30%42.4

SMA 50/200

0.97x53.2

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

14%57.3

FUNDAMENTALS

Market Cap

$1.6B

P/E (Forward)

—

Gross Margin

72.7%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 301207.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
301207.SZ	Hualan Biological Vaccine Inc.(you)	$1.6B	48	HOLD
688222.SS	HitGen Inc.	$1.8B	49	HOLD
688366.SS	Shanghai Haohai Biological Technology Co., Ltd.	$1.1B	48	HOLD
300497.SZ	Jiangxi Fushine Pharmaceutical Co., Ltd.	$1.2B	46	HOLD
600866.SS	Star Lake Bioscience Co., Inc.Zhaoqing Guangdong	$1.2B	46	HOLD
688513.SS	Chengdu Easton Biopharmaceuticals Co., Ltd.	$1.4B	53	HOLD
688319.SS	Chengdu Olymvax Biopharmaceuticals Inc.	$2.1B	43	HOLD
688739.SS	Liaoning Chengda Biotechnology Co.,Ltd.	$1.3B	41	HOLD
9969.HK	InnoCare Pharma Limited	$2.6B	49	HOLD
2171.HK	CARsgen Therapeutics Holdings Limited	$1.3B	41	HOLD

Peer medians: ROE 4.8% · P/E 27.6x · Gross margin 53.0%

Hualan Biological Vaccine Inc. (301207.SZ) — Stock Score Summary

Hualan Biological Vaccine Inc. (301207.SZ) has a MoatMap StockRank of 48/100 based on Quality (56/100), Value (39/100), and Momentum (44/100) factor scores. The current signal is HOLD. Hualan Biological Vaccine is a domestic Chinese vaccine developer. It lacks the global scale, regulatory validation, and multi-product pricing power of high-conviction CDMOs, making it highly vulnerable to localized price bidding wars.

Key Financial Metrics

Price	$2.43
Market Cap	$1.6B
P/E (TTM)	53.52
Price/Book	1.72
Return on Equity	3.2%
Return on Invested Capital	3.3%
Gross Margin	72.7%
Operating Margin	73.1%
Revenue Growth	10.3%
Dividend Yield	8.3%
Free Cash Flow	$6M

Hualan Biological Vaccine Inc. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Hualan Biological Vaccine Inc.’s (301207.SZ) StockRank?: MoatMap’s StockRank for Hualan Biological Vaccine Inc. (301207.SZ) is 48/100, with a Hold signal. It is a composite of Quality (56), Value (39), and Momentum (44) factor ranks across MoatMap’s 20,000+ stock universe.
Does Hualan Biological Vaccine Inc. have an economic moat?: Hualan Biological Vaccine Inc. (301207.SZ) has a Quality factor score of 56/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Hualan Biological Vaccine Inc. a buy, hold, or sell?: MoatMap’s current signal for Hualan Biological Vaccine Inc. (301207.SZ) is Hold, based on a StockRank of 48/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Hualan Biological Vaccine Inc. in?: Hualan Biological Vaccine Inc. (301207.SZ) operates in the Healthcare sector, specifically the Biotechnology industry (China).